Tables S1-S12, Figure S1-S3 from Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

Abstract

<p>Table S1: Summary of baseline characteristics for the current analysis cohort vs. the Remainder of HERA patients Table S2: Summary of Disease-free Survival by subgroup of patients Table S3: Summary of Overall Survival by subgroup of patients Table S4: Comparison of median follow-up time (based on reverse censoring for OS) Table S5: Predictive effect of p27 biomarker (Low/High) for DFS: Cox proportional hazards model without adjustment for other variables. Table S6: Predictive effect of p27 biomarker (Low/High) for DFS, adjusted for variables of clinical interest: Multivariate Cox proportional hazards model. Table S7: Predictive effect of p27 biomarker (Low/High) for DFS, adjusted for variables of clinical interest and the predictive effect of ER Local: Multivariate Cox proportional hazards model Table S8: Predictive effect of p27 biomarker (Low/High) for DFS, adjusted for variables of clinical interest and the predictive effect of ESR1: Multivariate Cox proportional hazards model Table S9: Predictive effect of cyclin D1 biomarker (continuous) for DFS: Multivariate Cox proportional hazards model without adjustment for other variables. Table S10: Predictive effect of cyclin D1 (continuous) biomarker for DFS, adjusted for variables of clinical interest: Multivariate Cox proportional hazards model. Table S11: Predictive effect of cyclin D1 biomarker (continuous) for DFS, adjusted for variables of clinical interest and the predictive effect of ER Local: Multivariate Cox proportional hazards model Table S12: Predictive effect of cyclin D1 biomarker (continuous) for DFS, adjusted for variables of clinical interest and the predictive effect of ESR1: Multivariate Cox proportional hazards model Figure S1. A: Histogram of TOPO2A biomarker Figure S1.B Histogram of Ki67 biomarker Figure S1.C: Histogram of Cyclin D1 biomarker Figure S1.D: Histogram of p27 biomarker Figure S2.A: Ki67 distribution by TOPO2A level Figure S2.B: Cyclin D1 distribution by TOPO2A level Figure S2.C: p27 distribution by TOPO2A level Figure S3.A: Ki67 distribution by Cyclin D1 level Figure S3.B: p27distribution by Cyclin D1 level</p>